Foresee Pharmaceuticals Co., Ltd. announced the initiation of patient dosing in the Phase II/III clinical trial of FP-025, its highly selective oral MMP-12 inhibitor, in adult patients with severe to critical COVID-19 with associated Acute Respiratory Distress Syndrome.
[Foresee Pharmaceuticals Co., Ltd.]
0